axl/mer inhibitor incb081776
Generic: Axl/Mer Inhibitor INCB081776
axl/mer inhibitor incb081776: 2 clinical trials tracked.
axl/mer inhibitor incb081776 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about axl/mer inhibitor incb081776, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
Pilot Study of INCB081776 Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade With Pembrolizumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary endpoint: Incidence of Adverse Events (AEs)
Interventionalopen10 targetStarted 2024-09Completion 2026-101 site · United StatesUniversity of Wisconsin, Madison
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Primary endpoint: Part 1 (1A and 1B): Number of treatment-emergent adverse events (TEAEs)
Interventionalopen83 targetStarted 2018-08Completion 2025-0918 sites · Denmark, Netherlands, Norway, Sweden…Incyte Corporation